AbbVie and AstraZeneca settle cancer drug patent suits
AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.
Cancer Research UK leads transatlantic early detection project
Cancer Research UK has announced a new research collaboration aimed at discovering new technologies to enable the early detection of cancer.
Paul Hastings boosts New York practice
Former Holland & Knight trial lawyer Merri Moken has joined Paul Hastings’ team in New York as of counsel.
LSPN 19: choose your IP strategy wisely, warn IP experts
Choosing the right IP strategy is crucial for companies, but constrained budgets and picking the wrong partners are all factors that can steer companies off the correct path.
10x Genomics to pay Becton Dickinson $25m settlement
US biotechnology company 10x Genomics is to pay its competitor, Becton Dickinson, $25 million as part of a deal to end worldwide patent infringement litigation between the companies.
CRISPR Therapeutics to buy JV from Bayer
A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
US committee votes in favour of Pelosi’s drug pricing plan
The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
FDA announces record generic approvals in 2019
The US Food and Drug Administration has announced record approvals of generic drugs in 2019, amid growing pressure over drug prices in the US.
